[go: up one dir, main page]

EP0569703A3 - Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK. - Google Patents

Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK. Download PDF

Info

Publication number
EP0569703A3
EP0569703A3 EP19930105659 EP93105659A EP0569703A3 EP 0569703 A3 EP0569703 A3 EP 0569703A3 EP 19930105659 EP19930105659 EP 19930105659 EP 93105659 A EP93105659 A EP 93105659A EP 0569703 A3 EP0569703 A3 EP 0569703A3
Authority
EP
European Patent Office
Prior art keywords
hbnf
protein
treating
methods
viral infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19930105659
Other languages
German (de)
English (en)
Other versions
EP0569703A2 (fr
Inventor
Joseph Mark Backer
Michael Robert Ostrander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of EP0569703A2 publication Critical patent/EP0569703A2/fr
Publication of EP0569703A3 publication Critical patent/EP0569703A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19930105659 1992-04-24 1993-04-05 Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK. Withdrawn EP0569703A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/874,848 US5461029A (en) 1992-04-24 1992-04-24 Method of treating herpes viral infections using HBNF and MK proteins
US874848 2001-06-05

Publications (2)

Publication Number Publication Date
EP0569703A2 EP0569703A2 (fr) 1993-11-18
EP0569703A3 true EP0569703A3 (fr) 1994-10-26

Family

ID=25364702

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19930105659 Withdrawn EP0569703A3 (fr) 1992-04-24 1993-04-05 Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK.

Country Status (7)

Country Link
US (1) US5461029A (fr)
EP (1) EP0569703A3 (fr)
JP (1) JPH0625007A (fr)
AU (1) AU3717693A (fr)
CA (1) CA2094797A1 (fr)
TW (1) TW216397B (fr)
ZA (1) ZA932879B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348503B1 (en) 1996-02-12 2002-02-19 Meryl J. Squires Method and topical treatment composition for herpesvirus hominis
US6355684B1 (en) 1990-10-11 2002-03-12 Meryl J. Squires Antimicrobial treatment for herpes simplex virus and other infectious diseases
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US20090191288A1 (en) * 1996-02-12 2009-07-30 Squires Meryl J Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases
DE69733694T2 (de) * 1996-07-10 2006-07-06 Muramatsu, Takashi, Nagoya Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
AU756279B2 (en) * 1997-07-14 2003-01-09 Medical Therapies Limited Agents comprising Midkine or its inhibitor as active ingredient
US6221855B1 (en) 1999-03-11 2001-04-24 Wake Forest University Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
FR2792206B1 (fr) * 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
AU1453601A (en) * 1999-11-01 2001-05-14 Curagen Corporation Novel polypeptides and nucleic acids encoding same
AU1486801A (en) * 1999-11-15 2001-05-30 Curagen Corporation Novel growth factor polypeptides and nucleic acids encoding same
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
FR2846659B1 (fr) * 2002-10-30 2005-02-18 Centre Nat Rech Scient Fragments peptidiques du facteur harp inhibant l'angiogenese
JP4646070B2 (ja) * 2003-03-27 2011-03-09 メディカル セラピーズ リミテッド 関節炎関連遺伝子及びこれの関節炎検査等への利用
EP1644027B1 (fr) 2003-07-16 2014-04-09 Evotec International GmbH Utilisation de pleitrophine pour prevenir et traiter des maladies pancreatiques et / ou l'obesite et / ou le syndrome metabolique
US20100303935A1 (en) * 2009-05-29 2010-12-02 Squires Meryl J Medicinal Composition
WO2011115562A1 (fr) * 2010-03-18 2011-09-22 Egesten Medical Consulting Hb Composé antimicrobien
US8979982B2 (en) 2013-05-01 2015-03-17 Jordan Technologies, Llc Negative pressure vapor recovery system
WO2024144515A1 (fr) * 2022-12-29 2024-07-04 T.C. Ankara Universitesi Rektorlugu Traitement de maladies auto-immunes, virales, bactériennes et fongiques et utilisation de midkines, qui sont associées au traitement de ces maladies, dans la modulation de cytokines, les agents modulateurs qui fournissent des activités de midkine et la composition pharmaceutique comprenant ces agents
WO2024243516A1 (fr) * 2023-05-25 2024-11-28 Indiana University Research And Technology Corporation Compositions et méthodes pour le traitement de maladies et de troubles cornéens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474979A1 (fr) * 1990-08-20 1992-03-18 American Cyanamid Company Séquence du gène du facteur neurotrohpique liant l'héparine
EP0476233A1 (fr) * 1990-08-20 1992-03-25 American Cyanamid Company Gène MK humain et séquence de la protéine
WO1992021362A1 (fr) * 1991-06-03 1992-12-10 Farmitalia Carlo Erba S.R.L. Facteur de croissance nerveuse destine a la prophylaxie et au traitement des infections a virus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000198A1 (fr) * 1987-07-07 1989-01-12 Biotechnology Research Associates, J.V. Facteurs de croissance de fibroblastes recombinants
CA1323317C (fr) * 1987-01-16 1993-10-19 Allen R. Banks Production de facteur de croissance de fibroblastes
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
FI893530A7 (fi) * 1987-11-24 1989-07-21 Amgen Inc Fibroblasti-kasvutekijän analogeja

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474979A1 (fr) * 1990-08-20 1992-03-18 American Cyanamid Company Séquence du gène du facteur neurotrohpique liant l'héparine
EP0476233A1 (fr) * 1990-08-20 1992-03-25 American Cyanamid Company Gène MK humain et séquence de la protéine
WO1992021362A1 (fr) * 1991-06-03 1992-12-10 Farmitalia Carlo Erba S.R.L. Facteur de croissance nerveuse destine a la prophylaxie et au traitement des infections a virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. C. RAPRAEGER ET AL: "Requirement of Heparan Sulfate for bFGF-Mediated Fibroblast Growth and Myoblast Differentiation", SCIENCE, vol. 252, 21 June 1991 (1991-06-21), pages 1705 - 1708, XP002186716, DOI: doi:10.1126/science.1646484 *
CHEMICAL ABSTRACTS, vol. 114, no. 19, 13 May 1991, Columbus, Ohio, US; abstract no. 181791z, K. OKAZAKI ET AL: "BHV-1 adsorption is mediated by the interaction of glycoprotein gIII with heparinlike moiety on the cell surface" *
DARRELL WUDUNN ET AL: "Initial Interaction of Herpes Simplex Virus with Cells is Binding to Heparan Sulfate", JOURNAL OF VIROLOGY, vol. 63, no. 1, January 1989 (1989-01-01), pages 52 - 58 *
P. BÖHLEN ET AL: "HBNF and Mk, members of a novel gene family of heparin-binding proteins with potential roles in embryogenesis and brain function", PROGRESS IN GROWTH FACTOR RESEARCH, vol. 3, 1991, GB, pages 143 - 157 *

Also Published As

Publication number Publication date
EP0569703A2 (fr) 1993-11-18
TW216397B (fr) 1993-11-21
AU3717693A (en) 1993-10-28
JPH0625007A (ja) 1994-02-01
ZA932879B (en) 1994-08-24
CA2094797A1 (fr) 1993-10-25
US5461029A (en) 1995-10-24

Similar Documents

Publication Publication Date Title
EP0569703A3 (fr) Méthode de traitement et prévention d'infections virales utilisant HBNF et protéine MK.
DE69524365D1 (de) Verfahren zur Isolierung und Reinigung von 2'-Deoxy-2',2'-difluornucleosiden
DE69501817D1 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
DE3888205D1 (de) Verfahren zur behandlung von lungenaffektionen und zubereitungen dafür.
DE69415100D1 (de) Vliesstoffgegenstand zur Behandlung von Oberflächen, Verfahren zur Herstellung und Verwendung davon
DE69115921D1 (de) Verfahren zur behandlung und verwendung von abfallstoffen
DE69707607D1 (de) Enzymbehandeltes Hesperidin, Verfahren zur Herstellung und Verfahren zur Verwendung von enzymbehandeltem Hesperidin
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69533774D1 (de) Verfahren und system zur verteilten kontrolle von hardware
DE69400342D1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluor-2-Chlorethan und Pentafluorethan
DE59606485D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE3765137D1 (de) Verfahren und zusammensetzung zur vorbeugung und behandlung von virus-infektionen.
DE59606489D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DE59401744D1 (de) Verfahren zur Herstellung von Difluormethoxy- und Difluormethylthioarenen
DE59500393D1 (de) Verfahren zur Herstellung von Cyclopropylalkylketonen und 4,5-Dihydroalkylfuranen
DE69217192D1 (de) Verfahren zur Herstellung von 2-Alkoxymethylakrolein und seine Verwendung zur Herstellung von 3-Alkoxymethylchinolinen
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE3885090D1 (de) Zusammensetzung und verfahren zur behandlung von hepatitisvirusinfektionen unter verwendung von 1-(2'-deoxy-2'-fluoro-beta-d-arabinofuranosyl)-5-ethyluracil.
DE59606657D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
ATE211928T1 (de) Verfahren zur inaktivierung von viren in proteinen
DE69207051D1 (de) Substituierte Acetoxyazetidinonderivate und Verfahren zur Herstellung von 4-Acyloxyazetidinonderivate
DE59606488D1 (de) Verfahren zur Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
ATE208198T1 (de) Verwendung von aminopurinen antiviralen mitteln zur behandlung und prophylaxe der latenten herpes-virus infektionen
DE69428610D1 (de) Methoden zur kultivierung von infektiösem laryngotracheitis virus und von "egg-drop-syndrome" verursachendem virus
DE69823786D1 (de) Verfahren zur Herstellung und Methode zur Kristallisierung von 2-Azabicyclo(2.2.1)hept-5-en3-on

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMERICAN CYANAMID COMPANY

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17P Request for examination filed

Effective date: 19941205

18D Application deemed to be withdrawn

Effective date: 19971101